Introduction:
The companies Biovian and 3P Biopharmaceuticals have merged to form a new pan-European independent contract development and manufacturing organization (CDMO) called 3PBIOVIAN. The new entity aims to provide comprehensive development and manufacturing services for various protein expression systems and viral vectors, spanning from preclinical to commercial phases.
- 3PBIOVIAN is the result of the merger between Biovian and 3P Biopharmaceuticals, creating a new pan-European CDMO.
- The new group will offer end-to-end development and manufacturing services for all protein expression systems and viral vectors.
- 3PBIOVIAN will leverage manufacturing sites in Pamplona-Noáin (Spain) and Turku (Finland), as well as a commercial office in Boston, to meet customer needs.
- The board of directors includes industry veterans from Lonza Pharma, Sartorius, Resilience, and 4th Dimension Bioprocess.
- 3PBIOVIAN aims to establish itself as a leader in the international market for the development and manufacturing of advanced therapies.
Conclusion:
The merger between Biovian and 3P Biopharmaceuticals has resulted in the creation of 3PBIOVIAN, a new pan-European CDMO that aims to provide comprehensive services for protein expression systems and viral vectors. With manufacturing sites in Spain and Finland, along with a commercial office in Boston, 3PBIOVIAN is well-positioned to meet the diverse needs of its customers. The company’s board of directors, consisting of industry veterans, brings a wealth of experience to the organization. By combining technology, capabilities, and a focus on quality, 3PBIOVIAN strives to become a leader in the dynamic international market for advanced therapies.
